Results 241 to 250 of about 222,938 (359)

GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?

The Laryngoscope, EarlyView.
Alina Zgardau, Ryan Chin Taw Cheong, Kenny Peter Pang, Brian W. Rotenberg   +3 more
wiley   +1 more source

Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown

Obesity, EarlyView.
ABSTRACT Objective Obesity affects 42% of older adults, with rates continuing to rise. This a complex condition influenced by non‐modifiable as well as modifiable risk factors. The disease can be treated through modifications to diet, physical activity, and behavior and more recently through antiobesity medications (AOMs) and surgery. Treatment must be
Anna Pendrey, Javier Sevilla‐Martir
wiley   +1 more source

Effect of Glucagon-like Peptide-1 Receptor Agonists on Outcomes After Hip Hemiarthroplasty for Femoral Neck Fractures in Patients With Type 2 Diabetes. [PDF]

J Am Acad Orthop Surg Glob Res Rev
Box MW, Puga TB, Werthmann NJ, Liu Y, Riehl JT.   +4 more
europepmc   +1 more source

Understanding the Increasing Prevalence of Obesity in Patients With Type 1 Diabetes: Strategies for Improving Clinical Care

Obesity, EarlyView.
ABSTRACT The presence of excess weight is no longer a distinguishing feature between patients with type 1 diabetes (T1D) and those with type 2 diabetes (T2D). Obesity treatment in patients with T2D improves glycemic control and reduces or even eliminates medication burden.
Kathleen R. Ruddiman, Jessica K. Bartfield, Irl B. Hirsch   +2 more
wiley   +1 more source

Imeglimin suppresses glucagon secretion and induces a loss of α cell identity. [PDF]

Cell Rep Med
Tsuno T, Li J, Nishiyama K, Kawasawa YI, Inoue R, Ong Yajima E, Nishiyama A, Yabe SG, Kin T, Okochi H, Tamura T, Shapiro AMJ, Oyadomari S, Kitamura T, Terauchi Y, Shirakawa J.   +15 more
europepmc   +1 more source

One Year of Exercise After Weight Loss Increases Postprandial GLP‐1 Secretion in Contrast to Usual Activity or GLP‐1 Receptor Agonist Treatment

Obesity, EarlyView.
ABSTRACT Objective Incretin‐based obesity medication maintains weight loss by mimicking the appetite‐inhibiting hormone GLP‐1. Interestingly, chronic exercise may improve postprandial appetite control by increasing late postprandial secretion of endogenous GLP‐1.
Joachim Holt, Rasmus Michael Sandsdal, Sarah Byberg, Charlotte Janus, Christian Rimer Juhl, Julie Rehné Jørgensen, Bolette Hartmann, Bente Stallknecht, Jens Juul Holst, Sten Madsbad, Simon Birk Kjær Jensen, Signe Sørensen Torekov   +11 more
wiley   +1 more source

Quantitative temporal analysis of pancreatic islet T lymphocyte and macrophage infiltration heralded by serum IgE in congenic BioBreeding (BB) Gimap5^-/^- rats at risk for insulitis and acute onset diabetes. [PDF]

Inflamm Res
Jönsson J, Faxius L, Tångrot J, Vance K, Jerman S, Bowman D, Bogdani M, Ericsson P, Bennet R, Ramelius A, Lernmark Å.   +10 more
europepmc   +1 more source

Glucose‐Dependent Insulinotropic Polypeptide and Glucagon After Weight Loss Induced by Diet or Bariatric Surgery

Obesity, EarlyView.
ABSTRACT Objective This study compared the effects of a very low‐energy diet (VLED), alone or combined with sleeve gastrectomy (SG) or Roux‐en‐Y gastric bypass (RYGB), on glucose‐dependent insulinotropic polypeptide (GIP) and glucagon concentrations, hormones likely to play a role in weight loss maintenance.
Amanda Finn, Yenni Cedillo, Marthe Aukan, Barbara Gower, Catia Martins   +4 more
wiley   +1 more source

Topiramate Enhances GABAergic Tone to Orexigenic Neuropeptide Y/Agouti‐Related Peptide (NPY/AgRP) Neurons

Obesity, EarlyView.
ABSTRACT Objective Topiramate is a medication used off‐label, or in combination with phentermine, for the management of obesity. However, its mechanism of action remains elusive. As many obesity medications target the brain, we aimed to determine if topiramate influences the activity of hypothalamic melanocortin neurons known to regulate energy balance.
Moein Minbashi Moeini, Olivier Lavoie, Alexandre Caron, Kevin W. Williams, Natalie J. Michael   +4 more
wiley   +1 more source

Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide. [PDF]

Front Endocrinol (Lausanne)
Pieber TR, Svehlikova E, Urva S, Haupt A, Zhou C, Coskun T, Höller V, Fluhr G, Karanikas CA, Milicevic Z, Pratt EJ.   +10 more
europepmc   +1 more source